Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

First Posted Date
2023-01-06
Last Posted Date
2024-02-16
Lead Sponsor
Takeda
Target Recruit Count
52
Registration Number
NCT05673785
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

🇨🇳

Chongqing University Cancer Hospital, Chongqing, China

🇨🇳

The First Affiliated Hospital of Zhejiang University school of medicine, Hangzhou, China

and more 13 locations

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

First Posted Date
2023-01-05
Last Posted Date
2024-12-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
117
Registration Number
NCT05672459
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

First Posted Date
2023-01-05
Last Posted Date
2024-06-18
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
20
Registration Number
NCT05672173
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

First Posted Date
2022-12-27
Last Posted Date
2024-01-17
Lead Sponsor
Fen Li
Target Recruit Count
30
Registration Number
NCT05666336
Locations
🇨🇳

Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

First Posted Date
2022-12-27
Last Posted Date
2023-01-03
Lead Sponsor
Zhejiang University
Target Recruit Count
19
Registration Number
NCT05665075
Locations
🇨🇳

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

Natural Killer(NK) Cell Therapy in r/r AML

First Posted Date
2022-12-27
Last Posted Date
2023-01-03
Lead Sponsor
Zhejiang University
Target Recruit Count
18
Registration Number
NCT05665114
Locations
🇨🇳

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, China

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

First Posted Date
2022-12-27
Last Posted Date
2024-03-21
Lead Sponsor
Synthekine
Target Recruit Count
36
Registration Number
NCT05665062
Locations
🇺🇸

Roswell Park, Buffalo, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

City of Hope, Duarte, California, United States

and more 1 locations

HEM ISMART-D: Trametinib + Dexamethasone + Chemotherapy in Children with Relapsed or Refractory Hematological Malignancies

First Posted Date
2022-12-21
Last Posted Date
2024-11-11
Lead Sponsor
Princess Maxima Center for Pediatric Oncology
Target Recruit Count
26
Registration Number
NCT05658640
Locations
🇦🇹

St. Anna Kinderspital, Vienna, Austria

🇧🇪

Universitair Ziekenhuis Gent, Gent, Belgium

🇩🇰

Rigshospitalet Copenhagen, Copenhagen, Denmark

and more 33 locations

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

First Posted Date
2022-12-21
Last Posted Date
2023-03-03
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
100
Registration Number
NCT05660473
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, China

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

First Posted Date
2022-12-19
Last Posted Date
2022-12-19
Lead Sponsor
Shanghai Pudong Hospital
Target Recruit Count
204
Registration Number
NCT05656079
Locations
🇨🇳

Shanghai Pudong Hospital, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy